


**5rd REPORT OF
THE MALAYSIAN REGISTRY
of
RENAL BIOPSY 2012**



Editors :
**Rosnawati Yahya
Wan Jazilah Wan Ismail**

With contributions from:
Wan Shaariah, Sunita B, Yap Y C, Wong H S, Lee DG, Lim J Y, Premaa S, Tassha H A



Malaysian Society of Nephrology



Ministry of Health Malaysia

**5rd REPORT OF
THE MALAYSIAN REGISTRY
of
RENAL BIOPSY
2012**

Sponsors:
Malaysian Society of Nephrology

The National Renal Registry is funded with grants from:

**Roche
Ain Medicare
Baxter Healthcare
Fresenius Medical Care
Lucenxia
The Ministry of Health Malaysia**

June 2014
© National Renal Registry, Malaysia
ISSN 1985-6989



Published by:

The National Renal Registry
Malaysian Society of Nephrology
Suite 1604, Plaza Permata
No. 6, Jalan Kampar
50400 Kuala Lumpur
Malaysia

Telephone. : (603) 4045 8636
Direct Fax : (603) 4042 7694
e-mail : nrr@msn.org.my
Web site : <http://www.msn.org.my>

Cover illustration by Dr. Nik Hasimah Nik Yahya HKL

Important information:

This report is copyrighted. However it may be freely reproduced without the permission of the National Renal Registry. Acknowledgment would be appreciated. Suggested citation is:
Rosnawati Yahya, Wan Jazilah W I (Eds) 5th Report of the Malaysian Registry of Renal Biopsy 2012. Kuala Lumpur 2014.

This report is also published electronically on these websites <http://www.msn.org.my> or <https://www.macr.org.my/emrrb>.

ACKNOWLEDGEMENTS

The National Renal Registry would like to thank the following:

*All the nephrologists and staff of the participating hospitals
For their hard work and contribution,*

**The Ministry of Health, Malaysia
for support seen and unseen,**

For their generous support: -

Roche
Ain Medicare
Baxter Healthcare
Fresenius Medical Care
Lucenia

The staff of the Clinical Research Centre

&

*All who have in one way or another supported the National Renal
Registry.*

**NRR ADVISORY COMMITTEE MEMBERS
2012 TO 2014**

Members:	MSN appointment:	Facilities
Datuk Dr. Ghazali Ahmad	Chairman	Hospital Kuala Lumpur
Dr. Abdul Halim Abd Gafor	University representative	University Kebangsaan Malaysia Medical Centre
Dr. S. Prasad Menon	Private sector representative	Sime Darby Medical Centre Subang Jaya
Dr. Ong Loke Meng	CRC representative	Hospital Penang
Mr. Tam Chong Chiang	ADMAN representative	Hospital Tg. Ampuan Afzan
Dr. Lim Yam Ngo	MDTR sub-committee Chairperson	Hospital Kuala Lumpur
Dr. Wong Hin Seng	eMOSS sub-committee Chairperson	Hospital Selayang
Dr. Rosnawati Yahya	MRRB sub-committee Chairperson	Hospital Kuala Lumpur
Dr. Goh Bak Leong	MDTR Editor	Hospital Serdang
Dr. Rafidah Abdullah	Honorary MSN Treasurer	Hospital Selayang

Clinical Registry Manager

Lee Day Guat

Clinical Research Assistant

Suhazelini Ali

Choo Cheh Loo

Statistician

Adam bin Bujang

Premaa A/P Supramaniam

Tassha Hilda binti. Adnan

Nurakmal Baharum

MRRB WORKING COMMITTEE MEMBERS

Chairperson

Dr. Rosnawati Yahya

Members

Dr. Lim Soo Kun

Dr. Sunita Bavanandan

Dr. Wan Jazilah Wan Ismail

Dr. Wong Hin Seng

Dr. Yap Yoke Chin

ABOUT MALAYSIAN REGISTRY OF RENAL BIOPSY

Renal biopsy remains the main investigation in the diagnosis of renal diseases. In addition, it plays a major role in determining the management and prognosis of parenchymal renal disease. The collection of demographic, clinical and laboratory data at the time of biopsy and the set up of a database are useful tools for studying renal parenchymal diseases.

The development of a renal biopsy registry in each country promotes many advantages and these include comparison in incidence of renal diseases, identification of different policies and practices in renal biopsy in different areas, linkage with other registries such as dialysis or transplant registry and identification of rare renal diseases. Thus, the registry is a source of epidemiological data and would provide useful information in the planning of health care and in organizing prospective clinical studies.

The incidence of glomerular disease varies according to population, demographic characteristics, environmental factors, socio-economic status and the prevalence of infectious diseases. At present, there is limited information on the prevalence and incidence of glomerular disease, its potential disease burden and the temporal trend in Malaysia. Hence, the Malaysian Registry of Renal Biopsy (MRRB) was set up in 2005 to address this deficiency.

The MRRB collects information about patients who undergo renal biopsy in Malaysia. The MRRB is a new component of National Renal Registry (NRR), which has been operating the Malaysian Dialysis and Transplant Registry (MDTR) since 1993.


Objectives

The objectives of the MRRB registry are to:

1. Determine the disease burden attributable to glomerular disease (GD) by quantifying its incidence and prevalence, and its geographic and temporal trends in Malaysia.
2. Identify subgroups in the population at high risk of GD to whom preventive efforts should be targeted.
3. Identify potential causal and risk factors involved in GD.
4. Describe the clinical presentation and spectrum of GD.
5. Stimulate and facilitate basic, clinical and epidemiological research on GD.
6. Identify causes of allograft failure in our renal transplant population.
7. To audit the renal biopsy procedure, monitor both complications and quality of specimens in addition to identifying risk factors associated with complications.

Organization

The NRR organization is as follows:



Owner

The Malaysian Society of Nephrology (MSN) is the owner of this registry.

Sponsors

The MRRB is sponsored by the Malaysian Society of Nephrology (MSN) and the Ministry of Health, Malaysia.

NRR Advisory Committee

This is the committee established by the sponsors. The NRR Advisory Committee's role is to ensure that the MRRB stay focused on its objectives and to assure its continuing relevance and justification.

MRRB Steering Committee

The MRRB Working Committee supervises its operations.

National Renal Registry office

The NRR coordinating office is the designated coordinating center. It coordinates the data collection among the Source Data Providers (SDPs). It collaborates with Clinical Research Centre of Hospital Kuala Lumpur that provides epidemiological and statistical support for MRRB.

Source Data Providers (SDP)

These are centres that contribute the required data for MRRB. The SDP collects and enters data directly through the on-line web-base system. The pilot phase of the registry consists of SDPs from Ministry of Health.

Throughout this initial phase, we have refined and improved the database. In 2008, the registry is expanding to a national level to include participation from all nephrologists and renal physicians in Malaysia who perform renal biopsies. We hope the nephrology community will support us by submitting information, which is crucial to eventually improve the management of patients with Chronic Kidney Disease (CKD).

To participate in MRRB

Centres interested to participate in this registry please write in to NRR officially via post or email nrr@msn.org.my.

The following documents need to be completed and returned to facilitate participation.

- Centre Participation Self Reply Form
- Authorization Form
- Information Security Policy/User Agreement . One form per nominee as listed in the Authorization form. Users must have a personal mobile phone to received SMS authentication.

Upon receiving these documents, the centre shall be registered and each of the users of the MRRB shall be notified via their e-mail address.

Methodology

All patients from participating centres who undergo any kidney biopsy (native or graft) are to be enrolled into the registry.

On-line data submission is through MRRB web application or paper CRF. The data variables collected include demography, clinical presentation, and indication of biopsy, renal function, and laboratory data at presentation and at the time of biopsy, serological markers, virology status and histopathological result. In addition, an update on outcomes in terms of significant end-points such as end stage renal disease or death will be recorded annually.

List of Source Data Providers

Adult Centre Name	Sector	1st Report	2nd Report	3rd Report	4th Report	5th Report
96 Hospital Angkatan Tentera Lumut	Armed forces		√	√	√	√
Hospital Pakar Sultanah Fatimah Muar	MOH				√	√
Kuala Lumpur Hospital	MOH	√	√	√	√	√
Melaka Hospital	MOH	√	√	√	√	√
Pulau Pinang Hospital	MOH	√	√	√	√	√
Queen Elizabeth Hospital	MOH	√	√	√	√	√
Raja Perempuan Zainab II Hospital	MOH	√	√	√	√	√
Raja Permaisuri Bainun Hospital	MOH	√	√		√	√
Sarawak General Hospital	MOH	√	√	√	√	√
Selayang Hospital	MOH	√	√	√	√	√
Serdang Hospital	MOH		√	√	√	√
Sultanah Aminah Hospital	MOH	√	√	√	√	√
Sultanah Bahiyah Hospital	MOH	√	√	√	√	√
Sultanah Nur Zahirah Hospital	MOH	√	√	√	√	√
Tengku Ampuan Afzan Hospital	MOH	√	√	√	√	√
Tengku Ampuan Rahimah Hospital	MOH	√	√	√	√	√
Tuanku Ja'afar Hospital	MOH	√	√	√	√	√
Fan Medical Renal Clinic	Private		√	√	√	√
Ipoh Specialist Hospital	Private		√	√	√	√
KPJ Ampang Puteri Specialist Hospital	Private		√	√	√	√
KPJ Selangor Specialist Hospital	Private		√			
Lam Wah Ee Hospital	Private		√	√	√	√
Loh Guan Lye Specialist Centre	Private					√
Metro Specialist Hospital	Private		√	√	√	√
Normah Medical Specialist Centre	Private		√	√	√	√
Prince Court Medical Centre	Private			√	√	√
Sunway Medical Centre	Private		√	√	√	√
Teo Kidney Specialist Clinic	Private			√	√	√
Timberland Medical Centre	Private			√	√	√
Tung Shin Hospital	Private		√	√	√	
Pusat Perubatan Universiti Kebangsaan Malaysia	University					√
University Malaya Medical Centre	University		√	√	√	√
Universiti Sains Malaysia Hospital	University			√	√	√
All		13	26	28	30	31

Paediatric Centre Name	Sector	1 st Report	2 nd Report	3 rd Report	4 th Report	5 th Report
Kuala Lumpur Hospital	MOH	√	√	√	√	√
Likas Hospital	MOH	√	√	√	√	√
Pulau Pinang Hospital	MOH	√	√	√	√	√
Selayang Hospital	MOH	√	√	√	√	√
Sultan Ismail Hospital	MOH	√	√	√	√	√
Tengku Ampuan Afzan Hospital	MOH	√	√			
Tuanku Ja'afar Hospital (Paed)	MOH	√	√	√	√	√
		7	7	6	6	6

CONTRIBUTING EDITORS

Chapter	Title	Authors	Institutions
1	Overview of Renal Biopsy in Malaysia	Wan Sha'ariah Md Yusuf Lee Ming Lee Lee Day Guat	Tuanku Ja'afar Hospital Tuanku Ja'afar Hospital National Renal Registry
2	Primary Glomerulonephritis	Sunita Bavanandan Lim Soo Kun	Kuala Lumpur Hospital University Malaya Medical Centre
3	Secondary Glomerulonephritis	Rosnawati Yahya Kok Lai Sun Leong Chong Meng	Kuala Lumpur Hospital Pulau Pinang Hospital Sultanah Bahiyah Hospital
4	Paediatric Renal Biopsy	Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yoke Chin Mirunalini A/P Appadurai Selvakumar Sivapunniam	Tuanku Ja'afar Hospital Kuala Lumpur Hospital Pulau Pinang Hospital Sultan Ismail Hospital Selayang Hospital Kuala Lumpur Hospital Likas Hospital Tengku Ampuan Afzan Hospital
5	Renal Allograft Biopsy	Wong Hin Seng	Selayang Hospital

Report Editors

Rosnawati Yahya
Wan Jazilah Wan Ismail

CONTENTS

CHAPTER 1	OVERVIEW OF RENAL BIOPSY IN MALAYSIA	1
1.1	Introduction	2
1.2	Renal biopsies from the participating centres	2
1.2.1	Ascertainment rate of total biopsy performed	2
1.2.2	Type of renal biopsy performed	2
1.2.3	Number of renal biopsy done on each individual patient	2
1.2.4	Demographic distribution of renal biopsy (Native and Graft)	5
1.2.4.1	Age distribution	5
1.2.4.2	Gender distribution	6
1.2.4.3	Racial distribution	7
1.2.5	Renal biopsy report analysis	7
1.2.6	Histopathology specimen distribution to histopathology laboratories	8
1.3	Native kidney biopsy	11
1.3.1	Clinical Indications of renal biopsy	11
1.3.2	Histopathological diagnosis	12
1.3.3	Histopathology findings in common clinical presentation	14
1.3.3.1	Histopathological diagnosis in patients with nephrotic syndrome	14
1.3.3.2	Histopathological diagnosis in patients with urinary abnormalities	15
1.3.3.3	Histopathological diagnosis in patients with nephritic-nephrotic syndrome	16
1.3.3.4	Histopathological diagnosis in patients with nephritic syndrome	17
1.3.3.5	Primary GN according to various age group	18
CHAPTER 2	PRIMARY GLOMERULONEPHRITIS	19
2.1	Introduction	20
2.2	Minimal Change Disease (MCD)	20
2.2.1	Introduction	20
2.2.2	Patient population and characteristics	20
2.2.3	Clinical presentation	22
2.2.3.1	Clinical presentation by age	23
2.2.3.2	Clinical presentation by gender	26
2.2.4	Outcome of Minimal Change Disease	27
2.3	Focal Segmental Glomerulosclerosis (FSGS)	28
2.3.1	Introduction	28
2.3.2	Patient population and characteristics	28
2.3.3	Clinical Presentation	29
2.3.3.1	Clinical presentation by age	32
2.3.3.2	Clinical presentation by gender	34
2.3.4	Outcome of Focal Segmental Glomerulosclerosis	35
2.4	IgA Nephropathy (IgAN)	36
2.4.1	Introduction	36
2.4.2	Patient population and characteristics	36
2.4.3	Clinical presentation	37
2.4.3.1	Clinical Presentation by age	39
2.4.3.2	Clinical presentation by gender	42
2.4.4	Outcome of IgA Nephropathy	44

CONTENT *(con't)*

2.5	Idiopathic Membranous Nephropathy	45
2.5.1	Introduction	45
2.5.2	Patient population and characteristics	45
2.5.3	Clinical presentation	46
	2.5.3.1 Clinical presentation by age	48
	2.5.3.2 Clinical presentation by gender	50
2.5.4	Outcome of Idiopathic Membranous Nephropathy	51
CHAPTER 3	SECONDARY GLOMERULONEPHRITIS	53
3.1	Introduction	54
3.2	Lupus Nephritis	54
3.2.1	Introduction	54
3.2.2	Patient population and characteristics	54
	3.2.2.1 Age at time of biopsy	55
	3.2.2.2 Gender distribution	56
	3.2.2.3 Ethnic prevalence	56
3.2.3	Clinical presentation	57
	3.2.3.1 Clinical Presentation by age	58
	3.2.3.2 Clinical presentation by gender	60
	3.2.3.3 Clinical Presentations by histopathology	61
3.2.4	Renal function at presentation	63
	3.2.4.1 Renal function at presentation by age group	63
	3.2.4.2 Renal function at presentation by gender	64
	3.2.4.3 Renal function at presentation by histopathology	65
3.2.5	Histopathological diagnosis	67
	3.2.5.1 Histopathological diagnosis by age	67
	3.2.5.2 Histopathological diagnosis by gender	68
	3.2.5.3 Histopathological diagnosis by clinical presentation	68
3.2.6	Extra-renal involvement	69
	3.2.6.1 American Rheumatological Association (ARA) criteria in lupus nephritis	69
	3.2.6.2 ARA criteria in lupus nephritis by age	70
	3.2.6.3 ARA criteria in lupus nephritis by gender	70
	3.2.6.4 ARA criteria in lupus nephritis by histopathological findings	71
	3.2.6.5 Extra-renal involvement	71
3.2.7	Survival in lupus nephritis	73
	3.2.7.1 Death in patient with lupus nephritis	73
	3.2.7.2 Patient survival in lupus nephritis	74
	3.2.7.3 Renal survival in lupus nephritis	74
CHAPTER 4	PAEDIATRIC RENAL BIOPSY	77
4.1	Introduction	78
4.2	Number of patients and renal biopsies	78
	4.2.1 Total number of patients and native renal biopsies	78
	4.2.2 Number of patients from various hospitals	78
	4.2.3 Number of native renal biopsies	78
	4.2.4 Number of renal biopsy done on each individual patient	79
4.3	Outcome of renal biopsies	79
	4.3.1 Adequacy of renal biopsy for diagnosis	79
	4.3.2 Number of glomeruli obtained at each biopsy	79

CONTENT *(con't)*

4.4	Patient characteristics	80
4.5	Clinical presentation	80
4.5.1	Clinical presentation at biopsy	80
4.5.2	Renal function at biopsy	81
4.5.3	Hypertension at biopsy	81
4.6	Diagnosis of paediatric renal biopsies	82
4.7	Nephrotic syndrome	83
4.7.1	Renal histopathology diagnosis of children presenting with nephrotic syndrome	83
4.7.2	The histopathological profile in different steroid response categories	83
4.8	Renal histopathology diagnosis of children presenting with nephritic syndrome	84
4.9	Causes of severe renal failure (needed dialysis therapy)	84
4.10	Paediatric focal segmental glomerulosclerosis and minimal change disease	85
4.10.1	Characteristics of paediatric focal segmental glomerulosclerosis and minimal change disease among children with steroid resistant nephrotic syndrome	85
4.10.2	Patient survival in focal segmental glomerulosclerosis and minimal change disease	86
4.10.3	Renal survival of patient with focal segmental glomerulosclerosis and minimal change disease	87
4.11	Paediatric lupus nephritis	88
4.11	Biopsy failure and complications	88
4.11.1	Total number of patients and renal biopsies	88
4.11.2	Number of renal biopsy done on each individual patient with lupus	88
4.11.3	Patient characteristics of paediatric lupus nephritis	89
4.11.4	Extra renal manifestations of paediatric SLE	90
4.11.5	Classification of paediatric lupus nephritis	90
4.11.6	Patient survival in lupus nephritis	91
4.11.7	Renal survival of patients with lupus nephritis	91
4.12	Renal outcome	91
4.13	Biopsy failure and complication	92
4.13.1	Risk factors for biopsy failure	92
4.13.2	Risk factors for complications	93
	References	94
	CHAPTER 5 RENAL ALLOGRAFT BIOPSY	95
5.1	Introduction	96
5.2	Number of renal allograft biopsy	96
5.2.1	Number of renal allograft biopsy by year	96
5.2.2	Number of renal allograft biopsy by year and site	97
5.2.3	Number of renal allograft biopsy by year and age group	97
5.3	Clinical presentation at biopsy	97
5.4	Timing of renal allograft biopsy	97
5.5	Renal allograft biopsy Procedure	102
5.5.1	Renal allograft biopsy method	102
5.5.2	Number of passes	102
5.5.3	Number of glomeruli obtained on biopsy	102
5.5.4	Type of complications	102
5.6	Histological diagnosis	106
	Appendix I	xxiv
	Appendix II	xxvi
	Appendix III	xxix
	Appendix IV	xxiv

LIST OF TABLES

		Page
Table 1.2.1	Total number of renal biopsies performed by centres, 2005-2012	3
Table 1.2.2	Distribution of reported native and graft renal biopsies by centres, 2005-2012	4
Table 1.2.3 (a)	Distribution of native renal biopsy in patients by number of episodes, 2005-2012	5
Table 1.2.3 (b)	Distribution of renal allograft biopsy in patients by number of episodes, 2005-2012	5
Table 1.2.4.1 (a)	Age distribution of native renal biopsy, 2005-2012	5
Table 1.2.4.1 (b)	Age distribution of renal allograft biopsy, 2005-2012	6
Table 1.2.4.1 (c)	Age group distribution of reported renal biopsies by state, 2005-2012	6
Table 1.2.4.2 (a)	Gender distribution of native renal biopsy, 2005-2012	7
Table 1.2.4.2 (b)	Gender distribution of renal allograft biopsy, 2005-2012	7
Table 1.2.4.3 (a)	Racial distribution of native renal biopsy, 2005-2012	7
Table 1.2.4.3 (b)	Racial distribution of renal allograft biopsy, 2005-2012	7
Table 1.2.5	Number of glomeruli obtained at each biopsy by centres, 2005-2012	8
Table 1.2.6 (a)	Distribution of biopsy specimens to histopathology laboratories by participating centres, 2005-2012	9
Table 1.2.6 (c)	Summary of biopsies received by in house and external laboratories, 2007-2012	10
Table 1.2.6 (d)	Histopathology laboratories receiving renal biopsy specimens, 2005-2012	11
Table 1.3.1 (a)	Indications for native renal biopsies, 2005-2012	12
Table 1.3.1 (b)	Renal function at time of biopsy, 2005-2012	12
Table 1.3.2	Histopathology of all native renal biopsies, 2005-2012	13
Table 1.3.3.1	HPE diagnosis in patients presenting with nephrotic syndrome, 2005-2012	14
Table 1.3.3.2	HPE diagnosis in patients presenting with asymptomatic urine abnormalities, 2005-2012	15
Table 1.3.3.3	HPE diagnosis in patients presenting with nephritic-nephrotic syndrome, 2005-2012	16
Table 1.3.3.4	HPE diagnosis in patients presenting with nephritic syndrome, 2005-2012	17
Table 1.3.3.5	Primary GN according to the various age group, 2005-2012	18
Table 2.1	Primary Glomerulonephritis, 2005-2012	20
Table 2.2.2 (a)	Demographic characteristics for MCD, 2005-2012	21
Table 2.2.2 (b)	Age group at time of biopsy (years) for MCD, 2005-2012	21
Table 2.2.3 (a)	Clinical presentation for MCD, 2005-2012	22
Table 2.2.3 (b)	Presence of hypertension in MCD, 2005-2012	22
Table 2.2.3 (c)	Renal function in MCD by year, 2005-2012	23
Table 2.2.3.1 (a)	Clinical presentation by age group for MCD, 2005-2012	24
Table 2.2.3.1 (b)	Hypertension by age group for MCD, 2005-2012	24
Table 2.2.3.1 (c)	Renal function at presentation by age group for MCD, 2005-2012	25
Table 2.2.3.2(a)	Clinical presentation by gender for MCD, 2005-2012	26
Table 2.2.3.2(b)	Hypertension by gender for MCD, 2005-2012	26
Table 2.2.3.2 (c)	Renal function by gender for MCD, 2005-2012	27
Table 2.2.4 (a)	Patients survival estimates for death in MCD, 2005 2012	27
Table 2.2.4 (b)	Renal survival estimates for death in MCD, 2005 2012	28
Table 2.3.2 (a)	Demographic characteristics for FSGS, 2005-2012	28
Table 2.3.2 (b)	Age group at time of biopsy (years) for FSGS, 2005-2012	29
Table 2.3.3 (a)	Clinical presentation for FSGS, 2005-2012	30

LIST OF TABLES *(con't)*

Table 2.3.3 (b)	Presence of hypertension for FSGS, 2005-2012	30
Table 2.3.3 (c)	Renal function in FSGS by year, 2005-2012	31
Table 2.3.3.1 (a)	Clinical presentation by age group for FSGS, 2005-2012	32
Table 2.3.3.1 (b)	Hypertension by age group for FSGS, 2005-2012	32
Table 2.3.3.1 (c)	Renal function at presentation by age group for FSGS, 2005-2012	33
Table 2.3.3.2 (a)	Clinical presentation by gender for FSGS, 2005-2012	34
Table 2.3.3.2 (b)	Hypertension by gender in FSGS, 2005-2012	34
Table 2.3.3.2 (c)	Renal function by gender for FSGS, 2005-2012	35
Table 2.3.4 (a)	Patients survival estimates for death for FSGS, 2005 2012	35
Table 2.3.4 (b)	Renal survival estimates for death for FSGS, 2005 2012	36
Table 2.4.2 (a)	Demographic characteristics for IgAN, 2005-2012	36
Table 2.4.2 (b)	Age group at time of biopsy (years) for IgAN, 2005-2012	37
Table 2.4.3 (a)	Clinical presentation for IgAN, 2005-2012	38
Table 2.4.3 (b)	Presence of hypertension in IgAN, 2005-2012	38
Table 2.4.3 (c)	Renal function in IgAN by year, 2005-2012	39
Table 2.4.3.1 (a)	Clinical presentation by age group for IgAN, 2005-2012	40
Table 2.4.3.1 (b)	Hypertension by age group for IgAN, 2005-2012	40
Table 2.4.3.1 (c)	Renal function at presentation by age group for IgAN, 2005-2012	41
Table 2.4.3.2 (a)	Clinical presentation by gender for IgAN, 2005-2012	42
Table 2.4.3.2 (b)	Hypertension by gender for IgAN, 2005-2012	42
Table 2.4.3.1 (c)	Renal function by gender for IgAN, 2005-2012	43
Table 2.4.4 (a)	Patients survival estimates for death in IgAN, 2005 2012	44
Table 2.4.4 (b)	Renal survival estimates for death in IgAN, 2005 2012	44
Table 2.5.2 (a)	Demographic characteristics for IMN, 2005-2012	45
Table 2.5.2 (b)	Age group at time of biopsy (years) for IMN, 2005-2012	45
Table 2.5.3 (a)	Clinical presentation for IMN, 2005-2012	46
Table 2.5.3 (b)	Presence of hypertension in IMN, 2005-2012	47
Table 2.5.3 (c)	Renal function in IMN, 2005-2012	47
Table 2.5.3.1 (a)	Clinical presentation by age group for IMN, 2005-2012	48
Table 2.5.3.1 (b)	Hypertension by age group for IMN, 2005-2012	48
Table 2.5.3.1 (c)	Renal function at presentation by age group for IMN, 2005-2012	49
Table 2.5.3.2 (a)	Clinical presentation by gender for IMN, 2005-2012	50
Table 2.5.3.2 (b)	Hypertension by gender for IMN, 2005-2012	50
Table 2.5.3.2 (c)	Renal function by gender for IMN, 2005-2012	51
Table 2.5.4 (a)	Patients survival estimates for death in IMN, 2005 2012	51
Table 2.5.4 (b)	Renal survival estimates for death in IMN, 2005 2012	51
Table 3.1	Causes of secondary glomerulonephritis in adult, 2005-2012	54
Table 3.2.2.1(a)	Age group at time of biopsy (years), 2005-2012	55
Table 3.2.2.1(b)	Age group at time of biopsy (years), 2005-2012	55
Table 3.2.2.2	Gender distribution, 2005-2012	56
Table 3.2.2.3	Ethnic distribution, 2005-2012	56
Table 3.2.3	Clinical presentation by year, 2005-2012	57
Table 3.2.3(a)	Hypertension by year, 2005-2012	57
Table 3.2.3(b)	Renal function by year, 2005-2012	58
Table 3.2.3.1(a)	Clinical presentation by age group, 2005-2012	59
Table 3.2.3.1(b)	Hypertension by age group, 2005-2012	59
Table 3.2.3.1(c)	Renal function by age group, 2005-2012	60
Table 3.2.3.2(a)	Clinical presentation by gender, 2005-2012	60
Table 3.2.3.2(b)	Hypertension by gender, 2005-2012	61
Table 3.2.3.2(c)	Renal function by gender, 2005-2012	61

LIST OF TABLES *(con't)*

Table 3.2.3.3 (a)	Clinical presentations by histopathology in lupus nephritis, 2005-2012	62
Table 3.2.3.3 (b)	Hypertension by histopathology in lupus nephritis, 2005-2012	62
Table 3.2.3.3(c)	Renal function by histopathology, 2005-2012	63
Table 3.2.4.1	Renal function by age group in lupus nephritis, 2005-2012	64
Table 3.2.4.2	Renal function at presentation by gender, 2005-2012	65
Table 3.2.4.3	Renal function at presentation by histopathology, 2005-2012	66
Table 3.2.5	Histopathological diagnosis in lupus nephritis by year, 2005-2012	67
Table 3.2.5.1	Histopathological diagnosis by age group in lupus nephritis, 2005-2012	67
Table 3.2.5.2	Histopathological diagnosis by gender in lupus nephritis, 2005-2012	68
Table 3.2.5.3	Histopathological diagnosis by clinical presentation, 2005-2012	69
Table 3.2.6.1	ARA criteria in lupus nephritis, 2005-2012	69
Table 3.2.6.2	ARA criteria by age group, 2005-2012	70
Table 3.2.6.3	ARA criteria by gender, 2005-2012	70
Table 3.2.6.4	ARA criteria by histopathology, 2005-2012	71
Table 3.2.6.5 (a)	Extra-renal involvement by gender, 2005-2012	71
Table 3.2.6.5 (b)	Mucocutaneous involvement by gender in lupus nephritis, 2005-2012	72
Table 3.2.7.1	Death in patients with biopsy proven lupus nephritis, 2005-2012	73
Table 3.2.7.2	Patients survival estimates for death in lupus nephritis, 2005-2012	74
Table 3.2.7.3	Death censored renal survival estimates for lupus nephritis, 2005-2012	74
Table 4.2.2	Number of patients from various hospitals	78
Table 4.2.3	Number of renal biopsies	78
Table 4.2.4	Distribution of native renal biopsy in patients by number of attempts	79
Table 4.3.1	Conclusive report	79
Table 4.3.2	Number of glomeruli obtained at each biopsy	79
Table 4.4.1	Gender and racial distribution	80
Table 4.4.2	Age distribution	80
Table 4.5.1	Clinical presentation at biopsy	80
Table 4.5.2	Renal function at biopsy	81
Table 4.5.3(a)	Hypertension at biopsy	81
Table 4.5.3(b)	Type of antihypertensive drugs	81
Table 4.6	Diagnosis of paediatric renal biopsies	82
Table 4.7.1	Renal histopathology diagnosis of children presenting with nephrotic syndrome	83
Table 4.7.2	The histopathological profile in different steroid response categories	83
Table 4.8	Renal histopathology diagnosis of children presenting with nephritic syndrome	84
Table 4.9	Histology finding of children who had severe renal failure (needed dialysis therapy) who underwent renal biopsy	84
Table 4.10.1	Clinical characteristics of children with steroid resistant nephrotic syndrome, 2005-2012	85
Table 4.10.2	Patient survival for focal segmental glomerulosclerosis and minimal change disease, 2005-2012	86
Table 4.10.3	Death-censored renal survival of patient with focal segmental glomerulosclerosis and minimal change disease, 2005-2012	87
Table 4.11.1	Total number of patient and biopsies (SLE)	88
Table 4.11.2	Distribution of renal biopsy in patients with lupus by numbers of episodes, 2005-2012	88
Table 4.11.3.1	Gender distribution for paediatric lupus nephritis	88
Table 4.11.3.2	Ethnic distribution for paediatric lupus nephritis	88
Table 4.11.3.3	Age distribution for paediatric lupus nephritis	88

LIST OF TABLES *(con't)*

Table 4.11.3.4	Dialysis therapy for paediatric lupus nephritis at the time of biopsy	89
Table 4.11.3.5	Patient with hypertension (SLE)	89
Table 4.11.3.6	Clinical presentation at biopsy (SLE)	89
Table 4.11.4(a)	Clinical presentation of paediatric lupus	89
Table 4.11.4(b)	ARA criteria at presentation	89
Table 4.11.5	Classification of paediatric lupus nephritis	90
Table 4.11.6	Patients survival in lupus nephritis	90
Table 4.11.7	Death-censored renal survival of patients with lupus nephritis, 2005-2012	91
Table 4.12	Causes of end stage renal disease in children who underwent renal biopsy	92
Table 4.13.1	Frequency of complications	92
Table 4.13.2	Risk factors for complication	93
Table 5.2.1	Number of renal allograft biopsy, 2005-2012	96
Table 5.2.2	Number of renal allograft biopsy by centre, 2005-2012	98
Table 5.2.3	Renal allograft biopsy by year and age group, rate (per million population), 2005-2012	99
Table 5.3	Indications for renal allograft biopsy, 2005-2012	100
Table 5.4	Timing of renal allograft biopsy, 2005-2012	101
Table 5.5.1	Biopsy method, 2005-2012	103
Table 5.5.2	Number of passes, 2005-2012	103
Table 5.5.3	Number of glomeruli obtained on biopsy, 2005-2012	104
Table 5.5.4	Type of complications, 2005-2012	105
Table 5.6	Histological diagnosis, 2005-2012	105

LIST OF FIGURES

		Page
Figure 1.2.6(a)	Distribution of biopsy specimens to in house histopathology laboratories by participating centres, 2005-2012	10
Figure 1.2.6(b)	Distribution of biopsy specimens to external histopathology laboratories by participating centres, 2005-2012	10
Figure 1.3.3.5	Primary GN according to the various age group, 2005-2012	18
Figure 2.2.2 (a)	Demographic characteristics for MCD, 2005-2012	21
Figure 2.2.2 (b)	Age at time of biopsy (years) for MCD, 2005-2012	21
Figure 2.2.3 (a)	Clinical presentation for MCD, 2005-2012	22
Figure 2.2.3 (c)	Impaired renal function in MCD by year, 2005-2012	23
Figure 2.2.3.1 (a)	Clinical presentation by age group for MCD, 2005-2012	24
Figure 2.2.3.1 (b)	Hypertension by age group for MCD, 2005-2012	25
Figure 2.2.3.1 (c)	Renal function at presentation by age group for MCD, 2005-2012	25
Figure 2.2.3.2 (a)	Clinical presentation by gender for MCD, 2005-2012	26
Figure 2.2.3.2 (b)	Hypertension by gender for MCD, 2005-2012	26
Figure 2.2.3.2 (c)	Renal function by gender for MCD, 2005-2012	27
Figure 2.2.4 (a)	Patients survival estimates for death in MCD, 2005 2012	27
Figure 2.2.4 (b)	Renal survival estimates for death in MCD, 2005 2012	28

LIST OF FIGURES *(con't)*

		Page
Figure 2.3.2(a)	Demographic characteristics for FSGS, 2005-2012	29
Figure 2.3.2 (b)	Age at time of biopsy (years) for FSGS, 2005-2012	29
Figure 2.3.3 (a)	Clinical presentation for FSGS, 2005-2012	30
Figure 2.3.3 (b)	Presence of hypertension in FSGS, 2005-2012	30
Figure 2.3.3 (c)	Impaired renal function in FSGS by year, 2005-2012	31
Figure 2.3.3.1 (a)	Clinical presentation by age group for FSGS, 2005-2012	32
Figure 2.3.3.1 (b)	Hypertension by age group for FSGS, 2005-2012	33
Figure 2.3.3.1 (c)	Renal function at presentation by age group for FSGS, 2005-2012	33
Figure 2.3.3.2 (a)	Clinical presentation by gender for FSGS, 2005-2012	34
Figure 2.3.3.2 (b)	Hypertension by gender for FSGS, 2005-2012	34
Figure 2.3.3.2 (c)	Renal function at presentation by gender in FSGS, 2005-2012	35
Figure 2.3.4 (a)	Patients survival estimates for death in FSGS, 2005 2012	35
Figure 2.3.4 (b)	Renal survival estimates for death in FSGS, 2005 2012	36
Figure 2.4.2 (a)	Demographic characteristics for IgAN, 2005-2012	37
Figure 2.4.2 (b)	Age at time of biopsy (years) for IgAN, 2005-2012	37
Figure 2.4.3 (a)	Clinical presentation for IgAN, 2005-2012	38
Figure 2.4.3 (b)	Presence of hypertension in IgAN, 2005-2012	38
Figure 2.4.3 (c)	Renal function in IgAN by year, 2005-2012	39
Figure 2.4.3.1 (a)	Clinical presentation by age group for IgAN, 2005-2012	40
Figure 2.4.3.1 (b)	Hypertension by age group for IgAN, 2005-2012	41
Figure 2.4.3.1 (c)	Renal function by age group for IgAN, 2005-2012	41
Figure 2.4.3.2 (a)	Clinical presentation by gender for IgAN, 2005-2012	42
Figure 2.4.3.2 (b)	Hypertension by gender for IgAN, 2005-2012	43
Figure 2.4.3.2 (c)	Renal function by gender for IgAN, 2005-2012	43
Figure 2.4.4 (a)	Patients survival estimates for death in IgAN, 2005 2012	44
Figure 2.4.4 (b)	Renal survival estimates for death in IgAN, 2005 2012	44
Figure 2.5.2 (a)	Demographic characteristics for IMN, 2005-2012	46
Figure 2.5.2 (b)	Age at time of biopsy (years) for IMN, 2005-2012	46
Figure 2.5.3 (a)	Clinical presentation for IMN, 2005-2012	47
Figure 2.5.3 (b)	Presence of hypertension in IMN, 2005-2012	47
Figure 2.5.3.1 (a)	Clinical presentation by age group for IMN, 2005-2012	48
Figure 2.5.3.1 (b)	Hypertension by age group for IMN, 2005-2012	49
Figure 2.5.3.1 (c)	Renal function at presentation by age group for IMN, 2005-2012	49
Figure 2.5.3.2 (a)	Clinical presentation by gender for IMN, 2005-2012	50
Figure 2.5.3.2 (b)	Hypertension by gender for IMN, 2005-2012	50
Figure 2.5.3.2 (c)	Renal function by gender, 2005-2012	51
Figure 2.5.4 (a)	Patients survival estimates for death in IMN, 2005 2012	51
Figure 2.5.4 (b)	Renal survival estimates for death in IMN, 2005 2012	51
Figure 3.2.2.1	Age group at time of biopsy (years), 2005-2012	55
Figure 3.2.2.2	Gender distribution in lupus nephritis, 2005-2012	56
Figure 3.2.2.3	Ethnic distribution in lupus nephritis, 2005-2012	56
Figure 3.2.3	Clinical presentation by year, 2005-2012	57
Figure 3.2.3 (a)	Hypertension by year in lupus nephritis, 2005-2012	58
Figure 3.2.3 (b)	Impaired renal function by year in lupus nephritis, 2005-2012	58

LIST OF FIGURES *(con't)*

Figure 3.2.3.1 (a)	Clinical presentation by age group in lupus nephritis, 2005-2012	58
Figure 3.2.3.1 (b)	Hypertension by age group in lupus nephritis, 2005-2012	59
Figure 3.2.3.1 (c)	Impaired renal function by age group in lupus nephritis, 2005-2012	59
Figure 3.2.3.2 (a)	Clinical presentation by gender in lupus nephritis, 2005-2012	60
Figure 3.2.3.2 (b)	Hypertension by gender in lupus nephritis, 2005-2012	61
Figure 3.2.3.2 (c)	Impaired renal function by gender in lupus nephritis, 2005-2012	61
Figure 3.2.3.3 (a)	Clinical presentations by histopathology in lupus nephritis, 2005-2012	62
Figure 3.2.3.3 (b)	Hypertension by histopathology in lupus nephritis, 2005-2012	62
Figure 3.2.4.1	Renal function by age group in lupus nephritis, 2005-2012	64
Figure 3.2.4.2	Renal function at presentation by gender, 2005-2012	65
Figure 3.2.4.3	Renal function at presentation by histopathology, 2005-2012	66
Figure 3.2.5.3	Histopathological diagnosis by clinical presentation, 2005-2012	68
Figure 3.2.6.1	ARA criteria in lupus nephritis, 2005-2012	69
Figure 3.2.6.2	ARA criteria in lupus nephritis by age group, 2005-2012	69
Figure 3.2.6.3	ARA criteria in lupus nephritis by gender, 2005-2012	70
Figure 3.2.6.4	ARA criteria in lupus nephritis by histopathology, 2005-2012	70
Figure 3.2.6.5 (a)	Extra-renal involvement by gender in lupus nephritis, 2005-2012	72
Figure 3.2.6.5 (b)	Mucocutaneous involvement by gender in lupus nephritis, 2005-2012	72
Figure 3.2.7.1	Death from lupus nephritis	73
Figure 3.2.7.2	Patients survival estimates for death in lupus nephritis	74
Figure 3.2.7.3	Death censored renal survival estimates in lupus nephritis	75
Figure 4.10.2	Patient survival by focal segmental glomerulosclerosis and minimal change disease, 2005-2012	86
Figure 4.10.3	Renal survival by focal segmental glomerulosclerosis and minimal change disease, 2005-2012	87
Figure 4.11.6	Patients survival in lupus nephritis	90
Figure 4.11.7	Death-censored renal survival of patients with lupus nephritis	91
Figure 5.2.1	Number of renal allograft biopsy, 2005-2012	96
Figure 5.2.3	Renal allograft biopsy by year and age group, rate per million population 2005-2012	99
Figure 5.3	Indications for renal allograft biopsy, 2005-2012	100
Figure 5.4	Timing of renal allograft biopsy, 2005-2012	101
Figure 5.5.1	Biopsy method (censored for missing data), 2005-2012	102
Figure 5.5.2	Number of passes, 2005-2012	104
Figure 5.5.3	Number of glomeruli obtained on biopsy, 2005-2012	104
Figure 5.5.6	Histological diagnosis, 2005-2012	106

REPORT SUMMARY

CHAPTER 1: OVERVIEW OF RENAL BIOPSY IN MALAYSIA

This 5th report of Malaysian Registry of Renal Biopsy 2012 reports on renal biopsies performed from 1st January 2005 to 31st December 2012 .

- There were 45 participating centres from the years 2005-2012.
- In 2012, there were 15 adult and 8 paediatric Ministry of Health centres, 3 universities, 1 army hospital and 18 private centres.
- There were no new participating centres since 2010.
- There ascertainment rate has improved from 84.5% in 2010 to 95% in 2012.
- 9952 of 11219 renal biopsies that were performed from 2005-2012, were available for analysis.
- 8657(87%) of renal biopsies were done on native kidneys and 1295(13 %) were on renal allograft.
- There appeared to be more repeat graft biopsies in 2011-2012(52%) compared to the 2005-2010 period (42%).
- 66% of native kidney biopsies and 86 % of graft biopsies were done in the 15-45 years age group.
- 14 % of native kidney biopsies were done in paediatric age group less than 15 years.
- As in previous reports, native kidney biopsies were performed in more females (59.5%) compared to males (40.5%). This ratio remains unchanged since 2005.This was attributed to the higher number of females amongst patients diagnosed with SLE.
- The opposite was true for renal allograft biopsies where there were 63.5% males compared to 36.5% females.
- There were more Malays (58.1%) followed by Chinese (24.8%) in the native biopsy group. Chinese (55%) predominates in the renal allograft group.
- Seventy-five percent of biopsies received were conclusive. 24% had less than 10 glomeruli. 1.2 percent was classified as missing because the full HPE reports were not submitted to the registry.
- Fifty one percent of HPE slides were read locally and 48.4 % were sent to another centre. There is a gradual increase for biopsies to be read in the hospitals where biopsies were performed.
- Nephrotic syndrome was the leading indication for renal biopsy (40.9%) followed by asymptomatic urinary abnormalities (28.6%) and nephrotic-nephritic syndrome (9.6%).
- The commonest primary glomerulonephritis in adults were minimal change disease (32%) FSGS (29%) and IgA nephropathy (22%).
- Membranous glomerulonephritis constituted 9% of total primary glomerulonephritis.
- Lupus nephritis was the commonest secondary glomerulonephritis accounting for 80% followed by diabetic nephropathy at 11%.
- FSGS was the commonest primary glomerulonephritis in children less than 15 years age group (39.4%) followed by minimal change disease (34.7%)

CHAPTER 2: PRIMARY GLOMERULONEPHRITIS

The commonest primary glomerulonephritis found on adult kidney biopsies 2005-2012 were as follows: minimal change disease (32%), focal segmental glomerulosclerosis (29%) Ig A nephropathy (22%) and idiopathic membranous nephropathy (9%).

Caution had to be exercised when interpreting data on BP and eGFR as there were significant trends of missing data. Five year patient and renal survival rates are presented for the first time in this 5th report.

REPORT SUMMARY (con't)

Minimal Change Disease

- Accounted for 32% of total primary glomerulonephritis.
- 70% of patients present in the 15 to < 25 and 25 to < 35 age groups.
- There was a higher incidence of minimal change disease in males (65%) compared to females but there were no racial predilection.
- Nephrotic syndrome was the commonest clinical presentation at 78%.
- Most patients have normal BP (74%) and preserved renal function (73%) at presentation.
- The 5 year patient and renal survival was 94% and 98% respectively.

Focal Segmental Glomerulosclerosis

- Accounted for 29% of total primary glomerulonephritis.
- The mean age at presentation was 34.4 ± 14.6 years.
- Fifty- nine percent presented with nephrotic syndrome.
- The prevalence of hypertension and impaired renal function increased with age.
- The 5 year patient and renal survival was 86% and 87 % respectively.

IgA nephropathy

- This constituted 22% of primary glomerulonephritis
- 31.3% are between the ages of 15 to 45 years
- There is slight female preponderance (54% vs. 43%) which is contrary to what is reported in literature
- Asymptomatic urine abnormality remains the most common presentation. (51%)
- Hypertension is seen in 44.4% and eGFR < 60ml/min/1.73m² is observed in 47.1% at presentation.
- 5 year patient and renal survival were 93% and 78% respectively.

Idiopathic membranous nephropathy

- This constituted 9% of primary glomerulonephritis.
- The mean age at presentation is 45.30 ± 14.97 .
- There were no gender differences but there is a predilection for Chinese race.
- Sixty-seven percent presented with nephrotic syndrome.
- Hypertension was observed in 24.8% and renal impairment was seen increasingly as age advances.
- 5 year patient and renal survival were 85% and 92% respectively.

CHAPTER 3: SECONDARY GLOMERULONEPHRITIS

The commonest secondary GN reported was lupus nephritis. Diabetic nephropathy was the second commonest glomerular disease reported.

Lupus nephritis

- Accounted for 81% of total secondary GN.
- Mean age at the time of biopsy in adult lupus nephritis was 30.3 ± 10.7 years.
- Male to female ratio was 1 to 6.6
- Urine abnormality (35%) was the commonest clinical presentation followed by nephrotic syndrome (27.5%).
- The commonest histopathological finding was WHO or ISN/RPS class IV or IV+V (61.3 %).
- There was no clear correlation between histopathological findings and clinical presentation. However, class IV or class IV+V were more likely to present with symptomatic renal disease.

REPORT SUMMARY *(con't)*

- The prevalence of hypertension was higher in class IV or class IV +V.
- The prevalence of impaired kidney function correlated with histopathological findings. Class IV was more likely to have impaired renal function.
- About 60% of cases with lupus nephritis fulfilled 4 or more American Rheumatological Association (ARA) criteria at presentation.
- Fulfilling the ARA criteria does not predict the severity of renal lesion

CHAPTER 4: PAEDIATRIC RENAL BIOPSY

- 1224 renal biopsies were performed in 1113 children over a span of 13 years from 1999 until 2012.
- 95.6% of paediatric kidney biopsies were assessed to be adequate. This success is comparable to reports from Thailand, United Kingdom and Japan.
- There were slightly more girls (50.8 %) and this was attributed to the higher number of girls biopsied in the SLE group.
- The mean age at biopsy was 9.8± 4 years.
- The racial distribution was as follows: Malays (64%) Chinese (19 %) and Indians (7.1%)
- 37.2% were hypertensive at presentation. Calcium channel blockers and ACE inhibitors were the commonest anti-hypertensives prescribed.
- Nephrotic syndrome (50%) was the most frequent clinical diagnosis at presentation. Lupus nephritis contributed the largest group at 25 % followed by FSGS (21.4%) and minimal change disease (20.5%).
- When comparing FSGS and minimal change disease, FSGS had lower renal survival at 5 years. The renal survival for this group was 88% and 80% at 3 and 5 years respectively, whereas in the minimal change group the 3 and 5 years survival was 95% and 92% respectively.
- Patient survival was 91% and 87% at 3 and 5 years for FSGS group and was 96% and 91% at 3 and 5 years for minimal change group.
- In the paediatric lupus group that were dialysed at the time of biopsy the commonest HPE on biopsy was class IV or class V+IV.
- Renal survival for patients with lupus nephritis was 95.5% and 93.3% at 3 and 5 years respectively.
- 116 children were reported to the Malaysian Dialysis and Transplant Registry. The commonest causes of ESRD were FSGS (31.9%) advanced glomerulosclerosis (18.1%) lupus nephritis (11.2%) and IgA nephropathy. (9.5%)

CHAPTER 5: RENAL ALLOGRAFT BIOPSY

- The number of renal allograft biopsy reported has increased despite a decreasing number of new and existing renal transplant recipients for the past 8 years.
- Seventy-three percents of all renal allograft biopsies were performed in the four main transplant centres which are Hospital Kuala Lumpur, Hospital Selayang, University Malaya Medical centre and Prince court Medical Centre.
- Seventy-one percent of renal allograft biopsies were performed in the age group 25 to < 55 years.
- Gradual graft dysfunction as an indication for biopsy has increased 34.7 % in 2005 to 66.1% in 2012 (2 fold increase)
- About 40% of renal allograft biopsies were performed one year post renal transplantation.
- Rejection (acute and borderline) has remained the most common histological diagnosis and accounted for more than half of all allograft biopsies that were reported in 2012.
- The increasing trend of allograft biopsies with histological diagnosis of acute rejection appeared to have plateaued off in the last 2 years and in 2012 accounted for 38.3%.